<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62030">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835236</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 22/10</org_study_id>
    <secondary_id>2012-002556-17</secondary_id>
    <secondary_id>UNICANCER UC-0140/1207</secondary_id>
    <nct_id>NCT01835236</nct_id>
  </id_info>
  <brief_title>Trastuzumab &amp; Pertuzumab Followed by T-DM1 in MBC</brief_title>
  <official_title>A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In HER2-positive metastatic breast cancer, trastuzumab based treatment is the standard of
      care as long as there are no contraindications to trastuzumab. Frequently, trastuzumab is
      being combined with taxanes in the first-line setting. However, since therapy with
      trastuzumab is active even in the absence of chemotherapy in HER2-positive MBC, the optimal
      treatment strategy either in combination or in sequence with chemotherapy is still under
      debate. This randomized phase II trial is studying a new strategy for the treatment of
      metastatic breast cancer with HER2-positive. First-line treatment consists of trastuzumab
      and pertuzumab, a treatment without chemotherapy. In case of disease progression,
      chemotherapy with T-DM1 is then performed as second-line treatment. Third-line and further
      line therapies are performed according to the physician's discretion. If this new
      therapeutic strategy is as effective and better tolerated than the conventional strategy,
      this would mean a serious breakthrough in the treatment of HER2-positive metastatic breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

      -To evaluate the efficacy in terms of overall survival (OS) at 24 months of a
      chemotherapy-free dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed
      by T-DM1 (second-line) and of a chemotherapy-containing dual HER2-inhibition with
      trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) in patients with
      HER2-positive metastatic breast cancer.

      Secondary

        -  To evaluate other efficacy parameter

        -  To evaluate the safety and tolerability profile of the two treatment strategies

        -  To evaluate the Quality of Life (QoL)

        -  To learn how patients are treated after trial treatment

      OUTLINE: This is a multicenter study. Patients are stratified according to hormone receptor
      status (positive vs negative), prior trastuzumab (never or &gt;12 months vs â‰¤12 months after
      last infusion), visceral metastases (present vs absent) and site. Patients are randomized to
      1 of 2 treatment arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival (OS) - Analysis Population: ITT Population 1</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients being alive 24 months after randomization. A success is considered if a patient is alive at least 24 months after randomization. Analysis Population: ITT Population 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS - Analysis Population: ITT Population 2</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients being alive 24 months after randomization. A success is considered if a patient is alive at least 24 months after randomization. Analysis Population: ITT Population 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) of first-line treatment ignoring first Central Nervous System (CNS) lesion</measure>
    <time_frame>10 / 16 months (PFS will be calculated sustained from randomization until documented PD (ignoring first CNS lesion) or death, whichever occurs first during first-line treatment )</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS of first-line treatment ignoring first CNS lesion is the time from randomization to first event progression. A PFS of first-line treatment ignoring first CNS lesion event is defined as (whichever occurs first):
Disease progression (PD) after having received first-line treatment and prior to the next treatment
Death due to any reason Patients without events will be censored at last tumor assessment date without PFS ignoring first CNS lesion event during the first-line treatment period or prior to starting new treatment.
Analysis population: ITT Population 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of second-line treatment</measure>
    <time_frame>8 months (PFS will be calculated sustained from registration of second line treatment until documented PD, PD CNS or death, whichever occurs first during second-line treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS of second-line treatment is the time from registration of second-line treatment to progression. A PFS event of second-line treatment is defined as (whichever occurs first):
Disease progression after having received second-line treatment and prior to the next treatment
PD CNS after having received first-line treatment and prior to the next treatment
Death due any reason during the second-line treatment period Patients without events will be censored at last tumor assessment date without PD and PD CNS during the second-line treatment period or prior to starting new treatment.
Analysis Population: ITT Population 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of second-line treatment ignoring first CNS lesion</measure>
    <time_frame>9 months  (PFS will be calculated sustained from registration of second line treatment until documented PD (ignoring first CNS lesion) or death, whichever occurs first during second-line treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS of second-line treatment ignoring first CNS lesion is the time from registration of second-line treatment to the first event occurs. A PFS of second-line treatment ignoring first CNS lesion event is defined as (whichever occurs first):
Disease progression after having received second-line treatment and prior to the next treatment
Death due any reason during the second-line treatment period Patients without events will be censored at last tumor assessment date without PFS ignoring first CNS lesion event during the second-line treatment period or prior to starting new treatment.
Analysis Population: ITT Population 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to failure of strategy (TFS) of first- plus second-line treatment</measure>
    <time_frame>18 / 24 months (TFS will be calculated sustained from randomization until documented PD, PD CNS or death, whichever occurs first before starting third-line therapy )</time_frame>
    <safety_issue>No</safety_issue>
    <description>TFS of first plus second-line treatment is the time from randomization to TFS event occurs. A TFS event of first plus second-line treatment is defined as (whichever occurs first):
Disease progression after having received the first and second-line treatment and prior to the next treatment
PD CNS after having received first- and second-line treatment and prior to the next treatment
Death due to tumor prior to the third-line treatment Patients without events will be censored at last tumor assessment without PD and PD CNS during first and second-line treatment period or prior to starting new treatment.
Analysis Population: ITT Population 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival OS</measure>
    <time_frame>OS will be calculated from randomization until death (estimated median: 32 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS will be calculated from randomization until death. Patients still alive or lost of follow up are censored at their last date known alive.
Analysis Population: ITT Population 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (OR) of first-line treatment (based on investigator assessment)</measure>
    <time_frame>10 / 16 months (OR is defined as the best status of response CR or PR up to first progression or start of a new treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control (DC) of first-line treatment (based on investigator assessment)</measure>
    <time_frame>6 months (DC is defined as CR, PR or SD for 6 months after randomization and no PD at 6 month after randomization)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OR of second-line treatment (based on investigator assessment)</measure>
    <time_frame>9 months (OR is defined as the best status of response CR or PR after registration for second-line treatment up to second progression or start of a new treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DC of second-line treatment (based on investigator assessment)</measure>
    <time_frame>6 months (DC is defined as the response CR, PR or SD for 6 months after registration of second-line treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) according to the NCI CTCAE v4.0 of first-line treatment</measure>
    <time_frame>Throughout first-line treatment (estimated up to 16 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events are assessed by the NCI CTCAE v4.0. from registration until registration of second-line treatment or start of follow-up (which occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs according to the NCI CTCAE v4.0 of second-line treatment</measure>
    <time_frame>Throughout second-line treatment (estimated up to 9 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events are assessed by the NCI CTCAE v4.0.from second-line registration until PD or start of follow-up (which occurs first) plus 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs grade â‰¥2 until first progression (ignoring first CNS lesion)</measure>
    <time_frame>Throughout first-line treatment (estimated up to 16 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events are assessed by Common terminology criteria for adverse events (CTCAE) v4.0. From randomization until first progression (documented PD, PD CNS or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>At baseline and every 12 weeks (three-monthly) until progression or up to a maximum of 24 months during 1st line therapy. Within 3 weeks prior to registration, after 12 and 24 weeks during 2nd line therapy.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of third-line treatment</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS will be calculated sustained from start of third-line treatment to progression (PD, PD CNS or death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>HER2-positive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab, Pertuzumab, T-DM1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.
- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.</description>
    <arm_group_label>Trastuzumab, Pertuzumab, T-DM1</arm_group_label>
    <arm_group_label>Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>First administration (loading dose) 840 mg i.v. infusion over 60 min.
- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.</description>
    <arm_group_label>Trastuzumab, Pertuzumab, T-DM1</arm_group_label>
    <arm_group_label>Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Day 1, 8 and 15; every 4 weeks for â‰¥4 months 90 mg/m2 i.v. infusion</description>
    <arm_group_label>Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>First administration: Day 1 and 8  25 mg/m2 i.v. infusion
then day 1 and 8, every 3 weeks for â‰¥4 months 30 mg/m2 i.v. infusion</description>
    <arm_group_label>Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-DM1</intervention_name>
    <description>Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (Â± 10 min.) Subsequent doses: over 30 min. (Â± 10 min.)</description>
    <arm_group_label>Trastuzumab, Pertuzumab, T-DM1</arm_group_label>
    <arm_group_label>Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1</arm_group_label>
    <other_name>Trastuzumab emtansine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        SELECTION OF PATIENTS (MOST IMPORTANT CRITERIA)

        Inclusion criteria for first-line therapy

        â€¢ Histologically confirmed breast cancer with distant metastases

        Note:

          1. A biopsy from the primary tumor or a metastasis can be used for diagnosis.

          2. Patients with non-measurable lesions are eligible.

          3. Patients with inoperable, locally advanced breast cancer with lymph node metastases
             other than ipsilateral locoregional (axillary, infraclavicular, parasternal) or other
             distant metastases are eligible.

          4. Patients with bone metastases with or without bone targeted therapy (bisphosphonates,
             denosumab) are eligible.

          5. Patients with de-novo Stage IV disease are eligible.

               -  HER2-positive tumor according to central pathology testing for HER2

        Note:

          1. A formalin-fixed paraffin-embedded (FFPE) biopsy from the primary tumor or a
             metastasis has to be used for HER2 status determination. If a biopsy is available
             from a metastasis, the HER2 testing should be performed using the metastasis.

          2. Fine needle aspiration is not acceptable for HER 2 testing. â€¢ Women aged â‰¥18 years

             â€¢ WHO performance status 0 to 2

               -  Left Ventricular Ejection Fraction (LVEF) â‰¥50% as determined by either ECHO or
                  MUGA

               -  Adequate organ function, evidenced by the following laboratory results:

             Neutrophils &gt;1.5x109/L, platelets &gt;100x109/L, hemoglobin â‰¥90g/L, total bilirubin
             â‰¤1.5xULN (unless the patients has documented Gilbert's disease), AST â‰¤3xULN, ALT
             â‰¤3xULN, AP â‰¤2.5xULN (except in patients with bone metastases: AP â‰¤5xULN), creatinine
             â‰¤1.5xULN

             Exclusion criteria for first-line therapy

             â€¢ Prior chemotherapy for inoperable locally advanced or metastatic breast cancer

             Note:

             Prior neoadjuvant/adjuvant chemotherapy is allowed if doses for anthracyclines have
             not exceeded 720mg/m2 and 240mg/m2 for epirubicin and doxorubicin, respectively.

             - Re-exposure to paclitaxel is permitted, if the last dose of taxane was given at
             least 1 year before randomization.

             - Re-exposure to vinorelbine is permitted, if the last dose of vinorelbine was given
             at least 1 year before randomization.

               -  Prior anti-HER2 treatment for metastatic or inoperable breast cancer

             Note:

             Prior neoadjuvant/adjuvant anti-HER2 treatment with trastuzumab and/or lapatinib is
             allowed.

             â€¢ More than one endocrine treatment line for metastatic or inoperable breast cancer
             exceeding a duration of 1 month

             Note:

          1. Adjuvant endocrine treatment is not counted as one line.

          2. Patients progressing on endocrine treatment: this specific endocrine treatment must
             have been stopped at least 2 weeks prior to randomization.

             â€¢ Prior treatment with pertuzumab and/or T-DM1

             â€¢ Known leptomeningeal or CNS metastases

             Note:

             A brain MRI or CT scan is mandatory in case of clinical suspicion of CNS metastases.

             â€¢ Single bone metastasis treated with radiotherapy (if the bone metastasis is the
             only tumor lesion)

             Inclusion criteria for second-line therapy â€¢ At least one dose of trial therapy in
             the first-line treatment phase of this trial

             â€¢ â€¢ Proven disease progression on first-line therapy or radiotherapy of a bone
             metastasis

             Notes:

             First new parenchymal CNS metastases only do not count as progression requiring the
             initiation of second line trial treatment. Radiotherapy of a single area only for
             pain control is allowed and will not count as PD.

             â€¢ Adequate organ function, evidenced by the following laboratory results: Neutrophils
             &gt;1.5x109/L, platelets &gt;100x109/L, hemoglobin â‰¥90g/L, total bilirubin â‰¤1.5xULN (unless
             the patients has documented Gilbert's disease), AST â‰¤3xULN, AP â‰¤2.5xULN (except in
             patients with bone metastases: AP â‰¤5xULN), creatinine â‰¤1.5ULN

             â€¢ LVEF â‰¥50% as determined by either ECHO or MUGA

             â€¢ QoL questionnaire has been completed.

             Exclusion criteria for second-line therapy

             â€¢ Termination of first-line therapy with trastuzumab/pertuzumab due to unacceptable
             toxicity without objective evidence of disease progression

             â€¢ CNS metastases that are untreated, symptomatic, or require therapy to control
             symptoms, as well as a history of radiation, surgery, or other therapy, including
             steroids, to control symptoms from CNS metastases within 2 months (60 days) before
             registration

             â€¢ Peripheral neuropathy of CTCAE grade â‰¥3

               -  Interstitial lung disease (ILD) or pneumonitis grade â‰¥3

               -  Any other adverse event which has not recovered to CTCAE grade â‰¤1 (except
                  alopecia)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Huober, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrik Weder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HervÃ© Bonnefoi, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Institut BergoniÃ©, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Epie Boven, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VU University medical center Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Aline Gerard, PhD</last_name>
    <phone>+41 31 389 91 84</phone>
    <email>marie-aline.gerard@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Georges-FranÃ§ois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Crehange, MD</last_name>
      <phone>+33 3 80 73 75 18</phone>
      <email>gcrehange@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Crehange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Bedenne, MD</last_name>
      <phone>+33 3 80 29 37 50</phone>
      <email>lbedenne@u-bourgogne.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Bedenne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Bourgogne</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Martin, MD</last_name>
      <phone>+33 3 20 00 97 57</phone>
      <email>pmartin@centre-bourgogne.com</email>
    </contact>
    <investigator>
      <last_name>Philippe Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique FranÃ§ois ChÃ©nieux</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Genet, MD</last_name>
      <phone>+33 5 55 45 48 00</phone>
      <email>dg@imagemed-87.com</email>
    </contact>
    <investigator>
      <last_name>Dominique Genet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-4-72-11-7398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU la TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-FranÃ§ois Seitz, MD</last_name>
      <phone>+33 4 91 38 60 23</phone>
      <email>Jean-francois.SEITZ@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-FranÃ§ois Seitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH RÃ©gional de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RÃ©my Leloup, MD</last_name>
      <phone>+33 2 38 51 47 78</phone>
      <email>remy.leloup@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>RÃ©my Leloup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Jean</name>
      <address>
        <city>Perpignan Cedex</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza Khemissa Akouz, MD</last_name>
      <phone>+33 4 68 61 61 37</phone>
      <email>faiza.khemissa@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Faiza Khemissa Akouz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-55-765-6565</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Haut Leveque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Collet, MD</last_name>
      <phone>+33 5 56 55 64 38</phone>
      <email>denis.collet@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Collet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Meunier, MD</last_name>
      <phone>+33 2 99 28 90 03</phone>
      <email>bernard.meunier@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard Meunier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne - HÃ´pital Nord</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Phelip, MD</last_name>
      <phone>+33 4 77 82 83 20</phone>
      <email>j.marc.phelip@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Phelip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-3-88-252-401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31509</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Carrere, MD</last_name>
      <phone>+33 5 61 77 76 10</phone>
      <email>carrere.n@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Carrere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-24-747-3712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Razvan Popescu, MD</last_name>
      <phone>41-62-836-7800</phone>
      <email>Razvan.Popescu@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Razvan Popescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Schreiber, MD</last_name>
      <phone>41-62-838-6053</phone>
      <email>alexander.schreiber@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Alexander Schreiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuger Kantonsspital AG - Frauenklinik</name>
      <address>
        <city>Baar</city>
        <zip>6340</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph M. Honegger, MD</last_name>
      <phone>+41 41 399 32 00</phone>
      <email>christoph.honegger@zgks.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph M. Honegger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Caspar, MD</last_name>
      <phone>+41 56 486 25 11</phone>
      <email>clemens.caspar@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Caspar Clemens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Ulrich Ludwig, MD</last_name>
      <phone>41-61-685-8470</phone>
      <email>christian.ludwig@claraspital.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Ulrich Ludwig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Rochlitz, Prof</last_name>
      <phone>+41 61 265 50 74</phone>
      <email>crochlitz@uhbs.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Rochlitz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Rabaglio, MD</last_name>
      <phone>+41 31 632 41 14</phone>
      <email>manuela.rabaglio@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Manuela Rabaglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Borner, Prof.</last_name>
      <phone>41-32-324-3714</phone>
      <email>markus.borner@szb-chb.ch</email>
    </contact>
    <investigator>
      <last_name>Markus Borner, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Oberwallis</name>
      <address>
        <city>Brig</city>
        <zip>3900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Mengis Bay, MD</last_name>
      <phone>+41 27 970 36 60</phone>
      <email>catherine.mengisbay@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Catherine Mengis Bay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenz M. Jost, MD</last_name>
      <phone>41-61-436-3636</phone>
      <email>lorenz.jost@ksbh.ch</email>
    </contact>
    <investigator>
      <last_name>Lorenz M. Jost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Greuter, MD</last_name>
      <phone>+41 81 256 61 11</phone>
      <email>stefan.greuter@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Greuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil Zaman, MD</last_name>
      <phone>41-21-314-4658</phone>
      <email>khalil.zaman@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Khalil Zaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Berthold, MD</last_name>
      <phone>+41 21 314 80 83</phone>
      <email>Dominik.Berthold@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Dominik Berthold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Lohri, MD</last_name>
      <phone>41-61-925-2710</phone>
      <email>andreas.lohri@ksli.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Lohri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Aebi, Prof</last_name>
      <phone>+41 41 205 58 60</phone>
      <email>stefan.aebi@onkologie.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Aebi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <phone>+41 62 311 42 41</phone>
      <email>cuhlmann_ol@spital.ktso.ch</email>
    </contact>
    <investigator>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum fuer Tumordiagnostik und Praevention</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Morant, MD</last_name>
      <phone>41-71-243-0043</phone>
      <email>rmorant@sg.zetup.ch</email>
    </contact>
    <investigator>
      <last_name>Rudolf Morant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SpitalSTS AG Simmental-Thun-Saanenland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rauch</last_name>
      <phone>+41 33 226 26 45</phone>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas MÃ¼ller, MD</last_name>
      <phone>+41 52 266 25 52</phone>
      <email>andreas.mueller@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas MÃ¼ller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤ts Spital ZÃ¼rich</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Leo, MD</last_name>
      <phone>+41 44 255 51 50</phone>
      <email>cornelia.leo@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Cornelia Leo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>HER2-positive</keyword>
  <keyword>Metastases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
